Hyperhomocysteinemia Predicts Renal Function Decline: a Prospective Study in Hypertensive Adults

Overview

Journal Sci Rep

Specialty Science

Date 2015 Nov 11

PMID 26553372

Citations 33

Authors

Di Xie

Yan Yuan

Jiangnan Guo

Shenglin Yang

Xin Xu

Qin Wang

Youbao Li

Xianhui Qin

Genfu Tang

Yong Huo

Guangpu Deng

Shengjie Wu

Binyan Wang

Qin Zhang

Xiaobin Wang

Pu Fang

Hong Wang

Xiping Xu

Fanfan Hou

Affiliations

Soon will be listed here.

Abstract

Hyper-homocysteinemia (HHcy) is associated with microalbuminuria and glomerular injury in general and diabetic populations. However, HHcy's role in hypertensive patients was not studied. We investigated whether HHcy is an independent risk factor for renal function decline and development of chronic kidney disease (CKD) in hypertensive men and women. This was a community-based prospective cohort study of 2,387 hypertensive adults without CKD at baseline, with a mean follow-up of 4.4 years. Baseline and follow-up levels of plasma Hcy, folate, vitamin B12, blood pressure and other pertinent covariables were obtained. CKD was defined as an estimated glomerular filtration rate (eGFR) <60 ml/min/per 1.73 m(2) and an eGFR decline rate >1 ml/min/per 1.73 m(2)/year. There was a graded association between Hcy tertiles and eGFR decline. Subjects in the 3(rd) tertile of Hcy levels had an accelerated rate of eGFR decline and an increased risk of incident CKD, as compared with those in the 1st tertile, after adjusting for age, gender, baseline diabetes, SBP, BMI, smoking, dyslipidemia, eGFR, folate and vitamin B12 levels. In conclusion, in this prospective cohort of Chinese hypertensive adults, elevated baseline plasma Hcy can serve as an independent biomarker to predict renal function decline and incident CKD.

Citing Articles

Association between riboflavin intake and the risk of all-cause mortality of patients with chronic kidney disease: A retrospective cohort study.

Ren X, Wang R, Liu F, Wang Q, Chen H, Hou Y Medicine (Baltimore). 2024; 103(39):e39417.

PMID: 39331893 PMC: 11441935. DOI: 10.1097/MD.0000000000039417.

Is renal function the key to disease risk management in elevated homocysteine levels?.

Hirata A Hypertens Res. 2024; 47(7):1976-1977.

PMID: 38750221 DOI: 10.1038/s41440-024-01690-y.

Role of ferroptosis in chronic kidney disease.

Li S, Han Q, Liu C, Wang Y, Liu F, Pan S Cell Commun Signal. 2024; 22(1):113.

PMID: 38347570 PMC: 10860320. DOI: 10.1186/s12964-023-01422-8.

Time to Change Our Viewpoints to Assess Renal Risks in Patients with Solitary Kidneys beyond Traditional Approaches?.

Alp A, Saruhan E, Dogan E, Gibyeli Genek D, Huddam B J Clin Med. 2023; 12(21).

PMID: 37959350 PMC: 10649944. DOI: 10.3390/jcm12216885.

Association of hyperhomocysteinemia and chronic kidney disease in the general population: a systematic review and meta-analysis.

Chen W, Feng J, Ji P, Liu Y, Wan H, Zhang J BMC Nephrol. 2023; 24(1):247.

PMID: 37612681 PMC: 10463317. DOI: 10.1186/s12882-023-03295-y.

References

Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S . Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension. 2003; 41(6):1341-5. DOI: 10.1161/01.HYP.0000069699.92349.8C. View

MALINOW M, Nieto F, Szklo M, Chambless L, Bond G . Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. Circulation. 1993; 87(4):1107-13. DOI: 10.1161/01.cir.87.4.1107. View

Veeranna V, Zalawadiya S, Niraj A, Pradhan J, Ference B, Burack R . Homocysteine and reclassification of cardiovascular disease risk. J Am Coll Cardiol. 2011; 58(10):1025-33. DOI: 10.1016/j.jacc.2011.05.028. View

Boushey C, Beresford S, Omenn G, Motulsky A . A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995; 274(13):1049-57. DOI: 10.1001/jama.1995.03530130055028. View

den Heijer M, Rosendaal F, Blom H, Gerrits W, Bos G . Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost. 1998; 80(6):874-7. View

Hao L, Ma J, Stampfer M, Ren A, Tian Y, Tang Y . Geographical, seasonal and gender differences in folate status among Chinese adults. J Nutr. 2003; 133(11):3630-5. DOI: 10.1093/jn/133.11.3630. View

Ford E, Bowman B . Serum and red blood cell folate concentrations, race, and education: findings from the third National Health and Nutrition Examination Survey. Am J Clin Nutr. 1999; 69(3):476-81. DOI: 10.1093/ajcn/69.3.476. View

Madero M, Peralta C, Katz R, Canada R, Fried L, Najjar S . Association of arterial rigidity with incident kidney disease and kidney function decline: the Health ABC study. Clin J Am Soc Nephrol. 2012; 8(3):424-33. PMC: 3586973. DOI: 10.2215/CJN.07900812. View

Nygard O, Nordrehaug J, Refsum H, Ueland P, Farstad M, Vollset S . Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997; 337(4):230-6. DOI: 10.1056/NEJM199707243370403. View

10.

Qin X, Huo Y, Xie D, Hou F, Xu X, Wang X . Homocysteine-lowering therapy with folic acid is effective in cardiovascular disease prevention in patients with kidney disease: a meta-analysis of randomized controlled trials. Clin Nutr. 2013; 32(5):722-7. DOI: 10.1016/j.clnu.2012.12.009. View

11.

Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y . Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet. 2007; 369(9576):1876-1882. DOI: 10.1016/S0140-6736(07)60854-X. View

12.

Yi F, Zhang A, Li N, Muh R, Fillet M, Renert A . Inhibition of ceramide-redox signaling pathway blocks glomerular injury in hyperhomocysteinemic rats. Kidney Int. 2006; 70(1):88-96. DOI: 10.1038/sj.ki.5001517. View

13.

Jager A, Kostense P, Nijpels G, Dekker J, Heine R, Bouter L . Serum homocysteine levels are associated with the development of (micro)albuminuria: the Hoorn study. Arterioscler Thromb Vasc Biol. 2001; 21(1):74-81. DOI: 10.1161/01.atv.21.1.74. View

14.

Chen N, Yang F, Capecci L, Gu Z, Schafer A, Durante W . Regulation of homocysteine metabolism and methylation in human and mouse tissues. FASEB J. 2010; 24(8):2804-17. PMC: 2909276. DOI: 10.1096/fj.09-143651. View

15.

Klag M, Whelton P, Randall B, Neaton J, Brancati F, Ford C . Blood pressure and end-stage renal disease in men. N Engl J Med. 1996; 334(1):13-8. DOI: 10.1056/NEJM199601043340103. View

16.

Bostom A, Rosenberg I, Silbershatz H, Jacques P, Selhub J, DAgostino R . Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med. 1999; 131(5):352-5. DOI: 10.7326/0003-4819-131-5-199909070-00006. View

17.

Lee M, Wang H . Homocysteine and hypomethylation. A novel link to vascular disease. Trends Cardiovasc Med. 1999; 9(1-2):49-54. DOI: 10.1016/s1050-1738(99)00002-x. View

18.

Levey A, Stevens L, Schmid C, Zhang Y, Castro 3rd A, Feldman H . A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604-12. PMC: 2763564. DOI: 10.7326/0003-4819-150-9-200905050-00006. View

19.

Coresh J, Selvin E, Stevens L, Manzi J, Kusek J, Eggers P . Prevalence of chronic kidney disease in the United States. JAMA. 2007; 298(17):2038-47. DOI: 10.1001/jama.298.17.2038. View

20.

Wald D, Law M, Morris J . Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002; 325(7374):1202. PMC: 135491. DOI: 10.1136/bmj.325.7374.1202. View